Clinical evidence,
summarized in seconds.
OneRx summarises published medical evidence for doctors. Ask a clinical question. Get a cited answers in seconds, drawn from trusted medical sources and guidelines.
Clinical Validation · PRECISION-AI
Tested in real practice, not on
synthetic data.
A prospective study across three tertiary oncology centres in India. 110 real clinical queries, five high-burden cancer types, independently rated by board-certified oncologists. Reported to SPIRIT-AI, CONSORT-AI, and APPRAISE-AI standards.
93%
Clinical decision impact
Reinforced or changed the oncologist's decision
8×
Faster to a recommendation
389s to 47s, an 87.9% reduction
+1.69
Physician confidence gain
On a 5-point scale, p<0.001
Security & Standards
Built to clinical-grade standards.
CDSCO Registered
ORIGIN-South-DL/M/MD/034932
HIPAA compliant
Patient data protection
DPDP compliant
Indian data protection
SOC2 Type2
Operational security
ISO 27001
Information security
ISO 13485
Medical software
IEC 62304
Medical software
Clinicians in leading institutions who use OneRx are
AIIMS
Tata Memorial Cancer Institute
Max Healthcare Hospital
Sarvodaya Hospital
Safdarjung Hospital
Sir Ganga Ram Hospital
KIMS Hospital
Venkateshwar Hospital
Yashoda Hospital
Yatharth Hospital
Baptist Hospital
MNJ Institute of Oncology
Kamla Nehru Memorial Hospital
Renova Hospitals
HCGAIIMSTata Memorial Cancer InstituteMax Healthcare HospitalSarvodaya HospitalSafdarjung HospitalSir Ganga Ram HospitalKIMS HospitalVenkateshwar HospitalYashoda HospitalYatharth HospitalBaptist HospitalMNJ Institute of OncologyKamla Nehru Memorial HospitalRenova HospitalsHCG100+ hospitals where OneRx clinicians practise.
Proudly Built in India for the world.
In Active use across
8 countries.
From tertiary cancer centres in India to oncology practices across the Middle East, Central Asia, and Africa.
2,000+
clinicians
30,000+
queries answered
India
Nepal
Bahrain
Oman
Russia
Kazakhstan
Uzbekistan
ChadResearch and Media
OneRx, on the record
Published research on OneRx and independent coverage of our work. Every item links to the original, so you can read it in full and judge for yourself.
The Problem
More evidence than any doctor
can read.
And it grows every year. Two problems follow.
For Clinicians
No one can keep up.
The volume is impossible.
Three to four million papers a year. Ten thousand in oncology alone.
Guidelines move faster than memory.
Medical Guidelines and regulatory approvals update through the year. The next edition lands before the last is absorbed.
Decisions lean on recent reading.
Not on the full evidence. A system problem, not a clinician one.
For Hospitals
Ten doctors, ten standards.
Care varies by clinician.
Different sources and habits produce different conclusions for similar cases.
Evidence trails are scattered.
Across charts, notes, and memory. Hard to audit. Hard to defend.
Knowledge doesn't transfer.
Juniors inherit habits, not a shared, current evidence base.
Introducing OneRx
Medical AI platform for
evidence summary.
OneRx reads the literature, summarises what matters, and shows every source. The doctor decides. OneRx makes sure the right evidence is there when they do: current, cited, and matched to the patient.
⚡ Multiple Myeloma: Confirmed Diagnosis — Treatment & Evaluation Framework
Summary
NCCN v5.2026 establishes quadruplet therapy as the preferred induction regimen for newly diagnosed multiple myeloma (NDMM), with daratumumab + bortezomib + lenalidomide + dexamethasone (Dara-VRd) as the Category 1 preferred regimen for transplant-eligible patients — daratumumab/hyaluronidase-fihj (DARZALEX FASPRO, FDA-approved for NDMM both ASCT-eligible and ineligible) is the SC formulation of choice. WHO Wiley For relapsed/refractory disease, the FDA approved teclistamab (Tecvayli) + daratumumab/hyaluronidase-fihj (March 2026) for patients with ≥1 prior line including a PI and IMiD; belantamab mafodotin-blmf (Blenrep) + bortezomib + dexamethasone (October 2025) for ≥2 prior lines; and linvoseltamab-gcpt (Lynozyfic) (July 2025) for ≥4 prior lines. Ncgindia NCCN A critical FDA black-box warning applies: PD-1/PD-L1 inhibitors combined with thalidomide analogues + dexamethasone are contraindicated in MM due to increased mortality in two randomized trials. NCCN PubMed India: The National Cancer Grid (NCG) coordinates myeloma care across 380+ centers; VRd (bortezomib + lenalidomide + dexamethasone) remains the most cost-effective triplet (incremental cost ₹2,20,093/QALY), and daratumumab has demonstrated consistent efficacy and acceptable safety in Indian relapsed/refractory patients, though access to quadruplet regimens and ASCT infrastructure remains variable across centers. PubMed Ncgindia
…
Cited.
Every summary links to its source paper. Nothing invented.
Current.
When medical guidelines and regulatory approvals update, OneRx reflects it within a week.
Genomics-aware.
Reads NGS and sequencing reports, and maps findings to guideline-based options.
Honest.
When the evidence is thin or conflicting, OneRx says so.
How OneRx Works
Four steps. Every summary.
And it grows every year. Two problems follow.
Structure
Reads research, trials, and journals into one searchable base.
Align
Matches evidence to the cancer stage and current guidelines, so the summary fits the case.
Preserve
Keeps every citation. Traceable, reviewable.
Verify
Stays current with the guidelines themselves, so a summary is never built on a superseded guideline.
Quality of Evidence
Hours of searching, in seconds,
across departments.
Built for Clinicians
Tumour board prep
Cited, per question
An unfamiliar regimen
Confirm and cite
A guideline check, mid-consult
In the room
An NGS report to interpret
Mapped to NCCN / ESMO guidance
Built for Hospitals
Live in weeks
Integrates with your HIS
Cloud or on-premises
Your data policy, your choice
Audit-ready by default
A trail for every summary
Faster onboarding
New consultants up to speed sooner
Return on Investment
See the return. Move the numbers.
Built on PRECISION-AI data. Change the inputs to match your practice.
Evidence Lookups Per Day
8/ day
Saved Per Lookup
5.7minutes
Measured in PRECISION-AI: 389s → 47s.
46 min
returned per clinical day
4.2 hrs / week
Why OneRx
Sharper than a Search. Safer than a Chatbot.
Eight things set OneRx apart from a general chatbot or a medical search tool.
OneRx next to the tools doctors already try
Events & Insights
Where we've been.
Stay up to date with the latest events, conferences, and webinars where we showcase how OneRx is transforming the landscape of clinical decision-making. Watch key moments and insights from our most recent activities.
For Clinicians
Try OneRx.
Three questions free, no sign-up. Web, iOS, and Android.
For Hospitals
Bring one evidence standard to your department.
Talk to a clinical lead, not a sales rep.
